Keytruda

AstraZeneca and Daiichi Sankyo announce results for lung cancer therapy

Initial results for the combination therapy – with Merck’s Keytruda – show an overall response rate of 37% in patients with non-small cell lung cancer. ... therapies. The data presented demonstrated an overall response rate of 37% when Dato-DXd was

Merck’s Keytruda receives FDA approval for advanced endometrial cancer

The trial results showed that patients receiving Keytruda demonstrated an objective response rate of 46%. ... an objective response rate of 46% for certain patients with advanced endometrial carcinoma … treated with Keytruda.”.

Merck’s Keytruda combined with chemotherapy could benefit thousands of breast cancer patients

with Keytruda, which supplemented standard chemotherapy prior to surgery, with a follow-up treatment using Keytruda after surgery. ... After their surgery, patients continued to receive either Keytruda without chemotherapy, or placebo.

Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment

The study evaluated the combination of Lenvima plus Keytruda versus chemotherapy for patients diagnosed with advanced, metastatic, or recurrent endometrial carcinoma. ... The results presented demonstrated that the combination of Lenvima plus Keytruda

Keytruda gains eighth FDA approval this year

Keytruda’s first approval seven years ago was also in melanoma, said Dr Scot Ebbinghaus from Merck Research Laboratories. ... Since then, we have built on this foundation in melanoma and have expanded the use of Keytruda into earlier stages of this

[ Previous 5 results ] 1 2 3 4 5 6 7 8 9 10 [ Next 5 results ]